* Continued cautious market * '26e-'28e EBITA down 5-3% * Trading at 4.
* Entering 2026e in better shape * Early signs of an improving market * 7-5x EV/EBITA '26e-'28e, 16-...
* Q1 highlights long-term upside to margins * Adj. EBITA +0-2% on '26e-'28e; 8% CAGR '25-'28e * Near...
Redeye provides its estimates for Freemelt’s Q1 results and comments on some recent news.
Redeye comments on the recent phase Ia data from the Oxford-led BIO-002 study evaluating the RH5.
No longer a mere self-test company, NanoRepro has used the pandemic windfall from COVID tests and tr...
VNV saw its Q1 NAV decline 15.5% in USD terms q/q and reported an NAV per share of SEK 34 (-12.
We believe the market will appreciate BONESUPPORT's strong free cash flow and the upcoming triggers ...
* Adj. EBITA +16% y-o-y, 9% above Infront consensus * Beat driven by strong margins, while organic g...
Redeye comments on Evolution’s Q1-results which were close to our expectations, albeit with weaker-t...
Ahead of CapMan's Q1 2026 results on 6 May, we cut our EBIT estimates, mainly to reflect a lower lev...
No new information regarding the possible divestment of the ESL Shipping segment has been released.
We update our forecasts and Base Case following Lime’s Q1 2026 results, which came in slightly ahead...
Redeye comments on Vertiseit’s Q1 2026 report. While EBITDA-CAPEX was 32% below our expectations, dr...
H1 will be clearly slower than H2/26, as project execution will accelerate during the latter half of...
* Sales SEK 44m (-5% vs. ABGSCe), EBIT -5.5m (vs. -3.
Redeye gives a short comment on the announced rights issue.
The Top Picks Investment Committee remains active in a market that has finally started to move after...
Redeye comments on Neola Medical’s update regarding the analysis of the Swedish clinical study.
* Q1 sales of SEK 44m (-11% y-o-y), -5% vs. ABGSCe * EBIT SEK -5.
